Todd Michael Cooper, DO
Specialties
- Cancer and Blood Disorders Center
- Leukemia and Lymphoma Program
- High-Risk Leukemia Program
- Apheresis
- Children's Title: Section Head, Oncology; Director of the Pediatric Leukemia/Lymphoma Program
- Academic Title: Professor, Department of Pediatrics, University of Washington School of Medicine
- Foundation Title: Evans Family Endowed Chair in Pediatric Cancer
- Research Center: Ben Towne Center for Childhood Cancer and Blood Disorders Research
- On Staff Since: February 2015
-
Biography
Todd M. Cooper, DO, is an attending physician at Seattle Children's, professor of pediatrics at the University of Washington School of Medicine and the Evans Family Endowed Chair in Pediatric Cancer. Dr. Cooper is the section head of Oncology in the Cancer and Blood Disorders Center.Â
Dr. Cooper's interests and expertise focus on the development of new therapeutic strategies for the treatment of acute leukemia in children. He initially helped develop Seattle Children’s High-Risk Leukemia Program and served as co-director of the program for eight years. Prior to coming to Seattle, Dr. Cooper developed and provided leadership for phase 1 developmental therapeutics programs at the University of Alabama at Birmingham and Children's Healthcare of Atlanta/Emory University. Dr. Cooper has led phase 1 studies of new agents for relapsed acute leukemia in a variety of national consortia including the Therapeutic Advances for Childhood Leukemia Consortium, Pediatric Oncology Experimental Therapeutics Investigator Consortium and the Children's Oncology Group (COG) Consortium.
Dr. Cooper serves as the chair of the COG Myeloid Diseases Committee and actively collaborates internationally to help maintain a cohesive strategy for the treatment of children with acute leukemia. Dr. Cooper leads COG AAML1831, a COG phase 3 study for newly diagnosed children with AML. He is the co-lead of The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Initiative, an international clinical trial that matches children with novel targeted therapies based on centralized next-generation genomic sequencing. These opportunities have allowed him to engage with the Food and Drug Administration and European Medical Association in discussing individual new drugs and general clinical trial designs for children with relapsed acute leukemia.
He is intimately involved in the selection of new treatments and in designing and leading clinical trials, all with the goal of bringing positive change to the therapy of children diagnosed with AML, both nationally and internationally.
- Board Certification(s)
-
Pediatric Hematology-Oncology
- Education
-
Nova Southeastern University, Davie, FL
- Residency
-
University of South Alabama College of Medicine, Mobile, AL
- Fellowship
-
University of Texas MD Anderson Cancer Center, Houston, TX
- Research Focus Area
-
Novel Therapeutics
-
Related Resources
-
PedAL Initiative Makes Progress Against Pediatric High-Risk Leukemia
Seattle Children’s Dr. Todd Cooper leads the worldwide PedAL Initiative and the drive for better options for kids with blood cancers.
-
Patient Testimonials
-
Awards and Honors
Loading...Award Name Award Description Awarded By Award Date {{ award.name }} {{ award.description }} {{ award.organization }} {{ award.displayDate }} No Awards and Honors found for Todd Michael Cooper, DO
-
Publications
Loading...No Publications found for Todd Michael Cooper, DO
-
Presentations
Loading...Presentation Title Event Location Date {{ presentation.title }} {{ presentation.presentedAt }} {{ presentation.location }} {{ presentation.displayDate }} No Presentations found for Todd Michael Cooper, DO
-
Research Funding
Loading...Grant Title Grantor Amount Award Date {{ funding.title }} {{ funding.grantedBy }} {{ funding.amount }} {{ funding.displayDate }} No Research Funding found for Todd Michael Cooper, DO
-
Clinical Trials and Research Studies
Loading...{{ item.st }}
No clinical trials found for Todd Michael Cooper, DO.